Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-08
2008-01-08
Seaman, Margaret D. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S126000
Reexamination Certificate
active
07317022
ABSTRACT:
The invention provides novel benzoimidazolone-carboxamide 5-HT4receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4receptor activity, and processes and intermediates useful for preparing such compounds.
REFERENCES:
patent: 5223511 (1993-06-01), Turconi et al.
patent: 5753673 (1998-05-01), Ohuchi et al.
patent: 6002009 (1999-12-01), Cereda et al.
patent: 6117882 (2000-09-01), Schaus et al.
patent: 6281218 (2001-08-01), Cereda et al.
patent: 6593336 (2003-07-01), Mangel et al.
patent: 2002/0173505 (2002-11-01), Skogvall
patent: 2005/0148573 (2005-07-01), Katsu et al.
patent: 2005/0197335 (2005-09-01), Marquess et al.
patent: 2005/0228014 (2005-10-01), Marquess et al.
patent: 2006/0100236 (2006-05-01), Choi et al.
patent: 2006/0100426 (2006-05-01), Choi et al.
patent: 2006/0135764 (2006-06-01), Fatheree et al.
patent: 0 309 423 (1989-03-01), None
patent: 0 908 459 (1999-04-01), None
patent: 01298271 (1999-12-01), None
patent: WO 00/76500 (2000-12-01), None
Heeringen et al., “Prefrontal 5-HT2a receptor binding index, hopelessness and personality characteristics in attempted suicide”, Journal of Affective Disorders, vol. 74, 2003, pp. 149-158.
Weiss et al., “A genetic screen for mouse mutations with defects in serotonin responsiveness”, Molecular Brain Research, 2003, vol. 115, pp. 162-172.
Fisher et al., American Journal of Gastroenterology, “Tegaserod does notalter fasting or meal-induced biliary tract motility”, 2004, vol. 99, pp. 1342-1349.
Bouras et al., “Prucalopride Accelerates Gastrointestinal and Colonic Transit in Patients with Constipation without a Rectal Evacuation Disorder”, Gastroenterology, 120, pp. 354-360 (2001).
Briejer et al., “The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound”, European Journal of Pharmacology, 423, pp. 71-83 (2001).
Briejer et al., “Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs”, Neurogastroenterol. Mot., 13, pp. 465-472 (2001).
De Winter et al., “Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats”, Gut, 45, pp. 713-718 (1999).
Grider et al., “5-Hydroxytryptamine4receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine”, Gastroenterology, 115, pp. 370-380 (1998).
Gullikson et al., “SC-49518 enhances gastric emptying of solid andliquid meals and stimulates gastrointestinal motility in dogs by a 5-hydroxytryptamine4receptor mechanism”, The Journal of Pharmacology and Experimental Therapeutics, 264(1), pp. 240-248 (1992).
Langlois et al., “5-HT4 receptor ligands: applications and new prospects”, Journal of Medicinal Chemistry, 46(3), pp. 319-344 (2003).
Muller-Lissner et al., “Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation”, Aliment Pharmacol Ther, 21, pp. 11-20 (2005).
Schaus et al., “Synthesis and structure—activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives”, J. Med. Chem., 41, pp. 1943-1955 (1998).
Zelnorm®, Physicians Desk Reference, PDR® Electronic Library (TM), http://www.thomsonhc.com/pdrel/librarian/ND—PR/Pdr/PFPUI/a31qVUv1Ll1cXv/DDAK/ . . . Mar. 6, 2007.
Baxter et al., “Benzimidazolone derivatives act as 5-HT4receptor ligands in rat oesophagus”, European Journal of Pharmacology, 212, pp. 225-229 (1992).
Dumuis et al., “Characterization of a novel 5-HT4receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285”, Naunyn-Schmiedeberg's Arch Pharmacol, 345, pp. 264-269 (1992).
Dumuis et al., “Azabicycloalkyl benzimidazolone derivatives as a novel class of potent agonists at the 5-HT4receptor positively coupled to adenylate cyclase in brain”, Naunyn-Schmiedeberg's Arch Pharmacol, 343, pp. 245-251 (1991).
Tapia et al., “2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with Selective Affinity 5-HT4Receptor: Synthesis and Structure-Affinity and Structure-Activity Relationships of a New Series of Partial Agonist and Antagonist Derivatives”, J. Med. Chem., 42, pp. 2870-2880 (1999).
Turconi et al., “Azabicycloalkyl benzimidazolones: Interaction with serotonergic 5-HT3and 5-HT4receptors and potential therapeutic implications”, Drugs of the Future, 16(11), pp. 1011-1026 (1991).
Turconi et al., “Synthesis of a New Class of 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carobxylic Acid Derivatives as Highly Potent 5-HT3Receptor Antagonists”, J. Med. Chem., 33, pp. 2101-2108 (1990).
Kehlet et al., “Review of Postoperative Ileus”, The American Journal of Surgery, 182 (Suppl to Nov. 2001), pp. 3S-10S (2001).
Choi Seok-Ki
Fatheree Paul R.
Gendron Roland
Goldblum Adam A.
Long Daniel D.
Hagenah Jeffrey A.
Rahmani Niloofar
Saxon Roberta P.
Seaman Margaret D.
Theravance Inc.
LandOfFree
Benzoimidazolone-carboxamide compounds as 5-HT 4 receptors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzoimidazolone-carboxamide compounds as 5-HT 4 receptors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzoimidazolone-carboxamide compounds as 5-HT 4 receptors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2814563